Previous 10 | Next 10 |
THE WOODLANDS, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2021 financial results on Friday, July 30, 2021 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (...
THE WOODLANDS, Texas, June 25, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Association’s 81 st Scie...
"Steady as she goes" isn't enough for Lexicon; Zynquista really needs a partner to effectively compete in the market, particularly if upcoming trial data from AstraZeneca and Lilly/Boehringer are positive. There has been some movement by the FDA on Lexicon's attempt to get the agency ...
THE WOODLANDS, Texas, May 26, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1...
THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology’s 70 th Annual Scientific Session (ACC.21) being h...
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2021 Earnings Conference Call May 06, 2021, 05:00 PET Company Participants Chas Schultz - Executive Director of Corporate Communications & Patient Advocacy Lonnel Coats - President and Chief Executive Officer and Director Jeff Wade - Executive Vice ...
Lexicon Pharmaceuticals (LXRX): Q1 GAAP EPS of -$0.15 beats by $0.02.As of March 31, 2021, Lexicon had $141.4M in cash and investments, as compared to $152.3M as of December 31, 2020.Revenues for the three months ended March 31, 2021 were negligible as compared to $8M for the corresponding pe...
Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones....
THE WOODLANDS, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (...
THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside ch...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...